Page 65 - NobleCon21

Cocrystal Pharma, Inc.

SELECTED FINANCIAL ITEMS COCP
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit (2.04) (1.36) (1.12) NA (4.52)
Gross Margin NM NM NM NM NM
EBIT (3.23) (2.34) (2.11) (2.09) (9.77)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (3.27) (2.30) (2.06) (2.05) (9.67)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 13.46 10.66 8.51 10.45 10.45
Cash & Short Term Investments 9.86 6.92 4.77 7.73 7.73
% of Assets 73% 65% 56% 74% 74%
Current Assets -Total 11.58 8.83 6.77 8.78 8.78
% of Assets 86% 83% 80% 84% 84%
Total Liabilities 3.93 3.36 3.17 2.78 2.78
% of Assets 29% 31% 37% 27% 27%
Current Liabilities - Total 2.43 1.93 1.83 1.52 1.52
% of Assets 18% 18% 22% 15% 15%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 9.52 7.30 5.33 7.67 7.67
% of Assets 71% 69% 63% 73% 73%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.16) (2.94) (2.16) (1.36) (9.62)
Net Cash Flow - Investing 0.00 NA NA (0.01) (0.01)
Net Cash Flow - Financing NA NA NA 4.34 4.34

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference